Results · Apr-Jun 2026
RPG Life Sciences Q1 FY27 results
Sales grew 16% to ₹196 crore from ₹169 crore in Apr-Jun 2025.
Operating profit grew 23% to ₹43.6 crore, an operating margin of 22.3% (up 1.3 points from a year ago).
Net profit grew 16% to ₹30.6 crore from ₹26.3 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +11%, net profit +2%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 195.7 | 168.9 | +16% |
| Operating profit (EBITDA) | 43.6 | 35.5 | +23% |
| Operating margin | 22.3% | 21.0% | +1.3 pts |
| Net profit | 30.6 | 26.3 | +16% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.